Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


COVID-19: Daily Top 10 Papers


  Alzheimer's Disease

  Free Subscription


Articles published in Neurology

Retrieve available abstracts of 258 articles:
HTML format



Single Articles


    September 2021
  1. MILA-ALOMA M, Brinkmalm A, Ashton NJ, Kvartsberg H, et al
    CSF Synaptic Biomarkers in the Preclinical Stage of Alzheimer Disease and Their Association With MRI and PET: A Cross-sectional Study.
    Neurology. 2021 Sep 23. pii: WNL.0000000000012853.
    PubMed     Abstract available


  2. SCHINDLER S, Li Y, Buckles VD, Gordon BA, et al
    Predicting Symptom Onset in Sporadic Alzheimer Disease With Amyloid PET.
    Neurology. 2021 Sep 9. pii: WNL.0000000000012775.
    PubMed     Abstract available


  3. BUCIUC M, Josephs KA, Jones DT, Whitwell JL, et al
    Progressive Auditory Verbal Agnosia Secondary to Alzheimer Disease.
    Neurology. 2021 Sep 9. pii: WNL.0000000000012783.
    PubMed    


    August 2021
  4. FRISON E, Proust-Lima C, Mangin JF, Habert MO, et al
    Diabetes Mellitus and Cognition: Pathway Analysis in the MEMENTO Cohort.
    Neurology. 2021;97:e836-e848.
    PubMed     Abstract available


  5. SANDERS AE
    A Century-Old Problem: Cognition and Neuropsychiatric Symptoms in Alzheimer Disease.
    Neurology. 2021 Aug 20. pii: WNL.0000000000012616.
    PubMed    


  6. EIKELBOOM WS, van den Berg E, Singleton EH, Baart SJ, et al
    Neuropsychiatric and Cognitive Symptoms Across the Alzheimer Disease Clinical Spectrum: Cross-sectional and Longitudinal Associations.
    Neurology. 2021 Aug 19. pii: WNL.0000000000012598.
    PubMed     Abstract available


  7. LI J
    Alzheimer's Villanelle.
    Neurology. 2021 Aug 10. pii: WNL.0000000000012612.
    PubMed    


  8. PETERSEN RC
    Mild Cognitive Impairment Criteria in Alzheimer's Disease Neuroimaging Initiative: Meeting Biological Expectations.
    Neurology. 2021 Aug 2. pii: WNL.0000000000012588.
    PubMed    


    July 2021
  9. TAO Q, Alvin Ang TF, Akhter-Khan SC, Itchapurapu IS, et al
    Impact of C-Reactive Protein on Cognition and Alzheimer Disease Biomarkers in Homozygous Apolipoprotein E varepsilon4 Carriers.
    Neurology. 2021 Jul 15. pii: WNL.0000000000012512.
    PubMed     Abstract available


  10. BOCANCEA DI, Catharina van Loenhoud A, Groot C, Barkhof F, et al
    Measuring Resilience and Resistance in Aging and Alzheimer Disease Using Residual Methods: A Systematic Review and Meta-analysis.
    Neurology. 2021 Jul 15. pii: WNL.0000000000012499.
    PubMed     Abstract available


  11. GROTHE MJ, Moscoso A, Ashton NJ, Karikari TK, et al
    Associations of Fully Automated CSF and Novel Plasma Biomarkers With Alzheimer Disease Neuropathology at Autopsy.
    Neurology. 2021 Jul 15. pii: WNL.0000000000012513.
    PubMed     Abstract available


  12. POGGESI A
    Resilience and Resistance in Aging and Alzheimer Disease: Another Step to Fill the Gap Between Clinicians and Researchers.
    Neurology. 2021 Jul 15. pii: WNL.0000000000012500.
    PubMed    


  13. WILSON RS, Wang T, Yu L, Grodstein F, et al
    Cognitive Activity and Onset Age of Incident Alzheimer Disease Dementia.
    Neurology. 2021 Jul 14. pii: WNL.0000000000012388.
    PubMed     Abstract available


  14. SALLOWAY S, Cummings J
    Aducanumab, Amyloid Lowering, and Slowing of Alzheimer Disease.
    Neurology. 2021 Jul 7. pii: WNL.0000000000012451.
    PubMed    


    June 2021
  15. BUCIUC M, Duffy JR, Machulda MM, Graff-Radford J, et al
    Clinical, Imaging, and Pathologic Characteristics of Patients With Right Versus Left Hemisphere-Predominant Logopenic Progressive Aphasia.
    Neurology. 2021 Jun 4. pii: WNL.0000000000012322.
    PubMed     Abstract available


  16. JUTTEN RJ, Sikkes SAM, Van der Flier WM, Scheltens P, et al
    Finding Treatment Effects in Alzheimer Trials in the Face of Disease Progression Heterogeneity.
    Neurology. 2021;96:e2673-e2684.
    PubMed     Abstract available


  17. BUCKLEY RF, Knopman DS
    Cognitive Heterogeneity in Alzheimer Clinical Trials: Harnessing Noise to Achieve Meaningfulness.
    Neurology. 2021;96:1017-1018.
    PubMed    


    May 2021
  18. HUGHES TM, Hajjar I
    Is Late-onset Alzheimer Disease Spelled "ATV(N)"?
    Neurology. 2021 May 24. pii: WNL.0000000000012259.
    PubMed    


  19. DONADIO V, Wang Z, Incensi A, Rizzo G, et al
    In Vivo Diagnosis of Synucleinopathies: A Comparative Study of Skin Biopsy and RT-QuIC.
    Neurology. 2021;96:e2513-e2524.
    PubMed     Abstract available


  20. FRIEDMAN LG, McKeehan N, Hara Y, Cummings JL, et al
    Value-Generating Exploratory Trials in Neurodegenerative Dementias.
    Neurology. 2021;96:944-954.
    PubMed     Abstract available


  21. MAYBLYUM DV, Becker JA, Jacobs HIL, Buckley RF, et al
    Comparing PET and MRI Biomarkers Predicting Cognitive Decline in Preclinical Alzheimer Disease.
    Neurology. 2021 May 5. pii: WNL.0000000000012108.
    PubMed     Abstract available


  22. BALLARINI T, Melo van Lent D, Brunner J, Schroder A, et al
    Mediterranean Diet, Alzheimer Disease Biomarkers and Brain Atrophy in Old Age.
    Neurology. 2021 May 5. pii: WNL.0000000000012067.
    PubMed     Abstract available


  23. BELLAVER B, Ferrari-Souza JP, Uglione da Ros L, Carter SF, et al
    Astrocyte Biomarkers in Alzheimer Disease: A Systematic Review and Meta-analysis.
    Neurology. 2021 May 5. pii: WNL.0000000000012109.
    PubMed     Abstract available


  24. HAZRATI LN, Schwab N
    Embracing the Unknown in the Diagnosis of Traumatic Encephalopathy Syndrome.
    Neurology. 2021;96:835-836.
    PubMed    


    April 2021
  25. BOERWINKLE AH, Wisch JK, Chen CD, Gordon BA, et al
    Temporal Correlation of CSF and Neuroimaging in the Amyloid-Tau-Neurodegeneration Model of Alzheimer Disease.
    Neurology. 2021 Apr 30. pii: WNL.0000000000012123.
    PubMed     Abstract available


  26. KARCESKI S
    The Effects of Long-term Medication Use in Alzheimer Disease.
    Neurology. 2021;96:e2247-e2250.
    PubMed    


  27. XU H, Garcia-Ptacek S, Jonsson L, Wimo A, et al
    Long-term Effects of Cholinesterase Inhibitors on Cognitive Decline and Mortality.
    Neurology. 2021;96:e2220-e2230.
    PubMed     Abstract available


  28. ROBERTS G, Durcan Mrcpi R, Donaghy PC, Lawley S, et al
    Accuracy of Cardiac Innervation Scintigraphy for Mild Cognitive Impairment With Lewy Bodies.
    Neurology. 2021 Apr 21. pii: WNL.0000000000012060.
    PubMed     Abstract available


  29. HAMILTON CA, Matthews FE, Donaghy PC, Taylor JP, et al
    Progression to Dementia in Mild Cognitive Impairment With Lewy Bodies or Alzheimer Disease.
    Neurology. 2021 Apr 19. pii: WNL.0000000000012024.
    PubMed     Abstract available


  30. HOWARD E, Irwin DJ, Rascovsky K, Nevler N, et al
    Cognitive Profile and Markers of Alzheimer Disease-Type Pathology in Patients With Lewy Body Dementias.
    Neurology. 2021;96:e1855-e1864.
    PubMed     Abstract available


    March 2021
  31. QIAN J, Betensky RA, Hyman BT, Serrano-Pozo A, et al
    Association of APOE Genotype With Heterogeneity of Cognitive Decline Rate in Alzheimer Disease.
    Neurology. 2021 Mar 26. pii: WNL.0000000000011883.
    PubMed     Abstract available


  32. GOTTESMAN RF, Hamilton R
    Recruiting Diverse Populations in Clinical Trials: How Do We Overcome Selection Bias?
    Neurology. 2021;96:509-510.
    PubMed    


  33. KANG SH, Kim ME, Jang H, Kwon H, et al
    Amyloid Positivity in Alzheimer/Subcortical-Vascular Spectrum.
    Neurology. 2021 Mar 15. pii: WNL.0000000000011833.
    PubMed     Abstract available


  34. SMIRNOV DS, Galasko D, Hiniker A, Edland S, et al
    Related Heterogeneity in Pathologically Confirmed Sporadic Alzheimer Disease.
    Neurology. 2021 Mar 15. pii: WNL.0000000000011772.
    PubMed     Abstract available


  35. BARKHOF BF, Pressman PS
    Time Is of the Essence: Early Detection of Incipient Alzheimer Pathology.
    Neurology. 2021 Mar 2. pii: WNL.0000000000011739.
    PubMed    


    February 2021
  36. ROBINSON-PAPP J, Saylor D
    HIV in the Brain: From Devastating Dementia to White Matter Hyperintensities.
    Neurology. 2021 Feb 26. pii: WNL.0000000000011735.
    PubMed    


  37. HUYNH K, Piguet O, Kwok J, Dobson-Stone C, et al
    Clinical and Biological Correlates of White Matter Hyperintensities in Patients with Behavioral-variant Frontotemporal Dementia and Alzheimer Disease.
    Neurology. 2021 Feb 17. pii: WNL.0000000000011638.
    PubMed     Abstract available


  38. THERRIAULT J, Pascoal TA, Benedet AL, Tissot C, et al
    Frequency of Biologically Defined Alzheimer Disease in Relation to Age, Sex, APOE epsilon4, and Cognitive Impairment.
    Neurology. 2021;96:e975-e985.
    PubMed     Abstract available


  39. RENTZ DM, Papp KV, Mayblyum DV, Sanchez JS, et al
    Association of Digital Clock Drawing with PET Amyloid and Tau Pathology in Normal Older Adults.
    Neurology. 2021 Feb 15. pii: WNL.0000000000011697.
    PubMed     Abstract available


  40. DETERS K, Napolioni V, Sperling RA, Greicius MD, et al
    Amyloid PET imaging in self-identified non-Hispanic Blacks from the Anti-Amyloid in Asymptomatic Alzheimer's Disease (A4) Study.
    Neurology. 2021 Feb 10. pii: WNL.0000000000011599.
    PubMed     Abstract available


  41. FERREIRA D, Nordberg A, Westman E
    Author Response: Biological Subtypes of Alzheimer Disease: A Systematic Review and Meta-analysis.
    Neurology. 2021;96:238.
    PubMed    


  42. ULEMAN JF, Melis RJF, Olde Rikkert MGM
    Reader Response: Biological Subtypes of Alzheimer Disease: A Systematic Review and Meta-analysis.
    Neurology. 2021;96:237-238.
    PubMed    


  43. GANESH A, Galetta S
    Editors' Note: Biological Subtypes of Alzheimer Disease: A Systematic Review and Meta-analysis.
    Neurology. 2021;96:237.
    PubMed    


    January 2021
  44. JOSEPH-MATHURIN N, Wang G, Kantarci K, Jack CR Jr, et al
    Longitudinal Accumulation of Cerebral Microhemorrhages in Dominantly Inherited Alzheimer Disease.
    Neurology. 2021 Jan 25. pii: WNL.0000000000011542.
    PubMed     Abstract available


  45. SAJJADI SA, Ash S, Cappa S
    Glass half full: Preservation of memory in Alzheimer-related primary progressive aphasia.
    Neurology. 2021 Jan 13. pii: WNL.0000000000011404.
    PubMed    


  46. MESULAM MM, Coventry C, Kuang A, Bigio EH, et al
    Memory resilience in Alzheimer's disease with primary progressive aphasia.
    Neurology. 2021 Jan 13. pii: WNL.0000000000011397.
    PubMed     Abstract available


  47. BLAZHENETS G, Frings L, Ma Y, Sorensen A, et al
    Validation of the Alzheimer Disease Dementia Conversion-Related Pattern as an ATN Biomarker of Neurodegeneration.
    Neurology. 2021 Jan 6. pii: WNL.0000000000011521.
    PubMed     Abstract available


  48. JAGUST WJ, Landau SM
    Temporal Dynamics of Beta-amyloid Accumulation in Aging and Alzheimer's Disease.
    Neurology. 2021 Jan 6. pii: WNL.0000000000011524.
    PubMed     Abstract available


  49. TRELLE AN, Carr VA, Wilson EN, Swarovski MS, et al
    Association of CSF Biomarkers with Hippocampal-dependent Memory in Preclinical Alzheimer Disease.
    Neurology. 2021 Jan 6. pii: WNL.0000000000011477.
    PubMed     Abstract available


  50. THERRIAULT J, Pascoal TA, Savard M, Benedet AL, et al
    Topographic Distribution of Amyloid-beta, Tau, and Atrophy in Patients With Behavioral/Dysexecutive Alzheimer Disease.
    Neurology. 2021;96:e81-e92.
    PubMed     Abstract available


    December 2020
  51. KNOPMAN DS, Jagust WJ
    Alzheimer Disease Spectrum: Syndrome and Etiology from Clinical and PET Imaging Perspectives.
    Neurology. 2020 Dec 22. pii: WNL.0000000000011415.
    PubMed    


  52. KOYAMA AK, Irwin DJ
    Alzheimer disease biomarker profiles in dementia with Lewy bodies: Does A plus T spell D-L-B?
    Neurology. 2020;95:1076-1077.
    PubMed    


  53. GICAS KM, Honer WG, Wilson RS, Boyle PA, et al
    Association of serial position scores on memory tests and hippocampal-related neuropathologic outcomes.
    Neurology. 2020;95:e3303-e3312.
    PubMed     Abstract available


  54. PETTIGREW C, Soldan A, Wang J, Wang MC, et al
    Association of midlife vascular risk and AD biomarkers with subsequent cognitive decline.
    Neurology. 2020;95:e3093-e3103.
    PubMed     Abstract available


  55. PALMQVIST S, Eshaghi A
    Spatial distribution of tau and beta-amyloid pathologies and their role in different Alzheimer's disease phenotypes.
    Neurology. 2020 Dec 1. pii: WNL.0000000000011272.
    PubMed    


  56. LA JOIE R, Visani AV, Lesman-Segev OH, Baker SL, et al
    Association of APOE4 and clinical variability in Alzheimer disease with the pattern of tau- and amyloid-PET.
    Neurology. 2020 Dec 1. pii: WNL.0000000000011270.
    PubMed     Abstract available


    November 2020
  57. KARCESKI S
    How a buildup of abnormal proteins in the brain may be the key to understanding Alzheimer disease.
    Neurology. 2020;95:e2951-e2953.
    PubMed    


  58. YOUNAN D, Wang X, Casanova R, Barnard R, et al
    PM2.5 associated with gray matter atrophy reflecting increased Alzheimers risk in older women.
    Neurology. 2020 Nov 18. pii: WNL.0000000000011149.
    PubMed     Abstract available


  59. ILLAN-GALA I, Lleo A, Karydas A, Staffaroni AM, et al
    Plasma tau and neurofilament light in frontotemporal lobar degeneration and Alzheimer's disease.
    Neurology. 2020 Nov 16. pii: WNL.0000000000011226.
    PubMed     Abstract available


  60. GRAFF-RADFORD J, Knopman D, Jones D
    Author response: Cerebrospinal fluid dynamics disorders: Relationship to Alzheimer biomarkers and cognition.
    Neurology. 2020;95:846.
    PubMed    


  61. ALLALI G, Laticevschi T
    Reader response: Cerebrospinal fluid dynamics disorders: Relationship to Alzheimer biomarkers and cognition.
    Neurology. 2020;95:845-846.
    PubMed    


  62. SIEGLER JE 3RD, Galetta S
    Editors' note: Cerebrospinal fluid dynamics disorders: Relationship to Alzheimer biomarkers and cognition.
    Neurology. 2020;95:845.
    PubMed    


    October 2020
  63. KIM HR, Lee T, Choi JK, Jeong Y, et al
    Genetic variants beyond amyloid and tau associated with cognitive decline: A cohort study.
    Neurology. 2020;95:e2366-e2377.
    PubMed     Abstract available


  64. WEIGAND AJ, Bondi MW, Thomas KR, Campbell NL, et al
    Association of anticholinergic medications and AD biomarkers with incidence of MCI among cognitively normal older adults.
    Neurology. 2020;95:e2295-e2304.
    PubMed     Abstract available


  65. KERCHNER GA, Filippi M
    Abeta-PET pathology accumulation index: Ready for the clinic?
    Neurology. 2020 Oct 19. pii: WNL.0000000000011060.
    PubMed    


  66. LEUZY A, Lilja J, Buckley CJ, Ossenkoppele R, et al
    Derivation and utility of an Abeta-PET pathology accumulation index to estimate Abeta load.
    Neurology. 2020 Oct 19. pii: WNL.0000000000011031.
    PubMed     Abstract available


  67. BENNETT DA, Knopman DS
    Extending Alzheimer disease biomarker studies into the Hispanic community.
    Neurology. 2020;95:665-666.
    PubMed    


  68. NAG S, Barnes LL, Yu L, Wilson RS, et al
    Limbic-predominant age-related TDP-43 encephalopathy in Black and White decedents.
    Neurology. 2020;95:e2056-e2064.
    PubMed     Abstract available


  69. GERTJE EC, van Westen D, Panizo C, Mattsson-Carlgren N, et al
    Association of enlarged perivascular spaces and measures of small vessel and Alzheimers disease.
    Neurology. 2020 Oct 12. pii: WNL.0000000000011046.
    PubMed    


  70. KAPASI A, Yu L, Boyle PA, Barnes LL, et al
    Limbic-predominant age-related TDP-43 encephalopathy, ADNC pathology, and cognitive decline in aging.
    Neurology. 2020;95:e1951-e1962.
    PubMed     Abstract available


  71. CATRICALA E, Polito C, Presotto L, Esposito V, et al
    Neural correlates of naming errors across different neurodegenerative diseases: A FDG-PET study.
    Neurology. 2020 Oct 1. pii: WNL.0000000000010967.
    PubMed     Abstract available


    September 2020
  72. HANES J, Kovac A, Kvartsberg H, Kontsekova E, et al
    Evaluation of a novel immunoassay to detect p-Tau Thr127 in the CSF to distinguish Alzheimer disease from other dementias.
    Neurology. 2020 Sep 24. pii: WNL.0000000000010814.
    PubMed     Abstract available


  73. BRENOWITZ WD, Besser LM, Kukull WA, Keene CD, et al
    Clinician-judged hearing impairment and associations with neuropathologic burden.
    Neurology. 2020;95:e1640-e1649.
    PubMed     Abstract available


  74. SAN LEE J, Lee H, Park S, Choe Y, et al
    Association between APOE epsilon2 and Abeta burden in patients with Alzheimer- and Vascular-Type Cognitive Impairment.
    Neurology. 2020 Sep 14. pii: WNL.0000000000010811.
    PubMed     Abstract available


  75. CIRRITO JR, Wallace CE, Yan P, Davis TA, et al
    Effect of Escitalopram on Abeta levels and plaque load in an Alzheimer mouse model.
    Neurology. 2020 Sep 10. pii: WNL.0000000000010733.
    PubMed     Abstract available


  76. SCHREIBER S, DiFrancesco JC
    Impaired occipital cerebrovascular reactivity as a biomarker for vascular beta-amyloid.
    Neurology. 2020;95:415-416.
    PubMed    


  77. GUZMAN-VELEZ E, Martinez J, Papp K, Baena A, et al
    Associative memory and in vivo brain pathology in asymptomatic presenilin-1 E280A carriers.
    Neurology. 2020;95:e1312-e1321.
    PubMed     Abstract available


  78. BRENOWITZ WD, Filshtein TJ, Yaffe K, Walter S, et al
    Association of genetic risk for Alzheimer disease and hearing impairment.
    Neurology. 2020 Sep 2. pii: WNL.0000000000010709.
    PubMed     Abstract available


  79. LUO J, Agboola F, Grant E, Masters CL, et al
    Sequence of Alzheimer disease biomarker changes in cognitively normal adults: A cross-sectional study.
    Neurology. 2020 Sep 1. pii: WNL.0000000000010747.
    PubMed     Abstract available


    August 2020
  80. HUANG J, Zuber V, Matthews PM, Elliott P, et al
    Sleep, major depressive disorder and Alzheimer's disease: A Mendelian randomisation study.
    Neurology. 2020 Aug 19. pii: WNL.0000000000010463.
    PubMed     Abstract available


  81. KIM JW, Byun MS, Lee JH, Yi D, et al
    Serum albumin and beta-amyloid deposition in the human brain.
    Neurology. 2020;95:e815-e826.
    PubMed     Abstract available


  82. MOFRAD RB, Tijms BM, Scheltens P, Barkhof F, et al
    Sex differences in CSF biomarkers vary by Alzheimer's disease stage and APOE epsilon4 genotype.
    Neurology. 2020 Aug 11. pii: WNL.0000000000010629.
    PubMed     Abstract available


  83. VAN DER ZANDE JJ, Gouw AA, van Steenoven I, van de Beek M, et al
    Diagnostic and prognostic value of EEG in prodromal dementia with Lewy bodies.
    Neurology. 2020;95:e662-e670.
    PubMed     Abstract available


  84. LAM AD, Sarkis RA, Pellerin KR, Jing J, et al
    Association of epileptiform abnormalities and seizures in Alzheimer disease.
    Neurology. 2020 Aug 6. pii: WNL.0000000000010612.
    PubMed     Abstract available


  85. GONNEAUD J, Bedetti C, Binette AP, Benzinger TLS, et al
    Association of education with Abeta burden in preclinicial familial and sporadic Alzheimer disease.
    Neurology. 2020 Aug 5. pii: WNL.0000000000010314.
    PubMed     Abstract available


    July 2020
  86. ARENAZA-URQUIJO EM EM, Salvado G, Operto G, Minguillon C, et al
    Association of years to parent's sporadic onset and risk factors with neural integrity and Alzheimer's biomarkers.
    Neurology. 2020 Jul 31. pii: WNL.0000000000010527.
    PubMed     Abstract available


  87. BAUMEISTER SE, Karch A, Bahls M, Teumer A, et al
    Physical activity and risk of Alzheimer's disease: a two-sample Mendelian randomization study.
    Neurology. 2020 Jul 17. pii: WNL.0000000000010013.
    PubMed     Abstract available


  88. COLLIJ LE, Heeman F, Salvado G, Ingala S, et al
    Multi-tracer model for staging cortical amyloid deposition using PET imaging.
    Neurology. 2020 Jul 16. pii: WNL.0000000000010256.
    PubMed     Abstract available


  89. SAIF N, Niotis K, Dominguez M, Hodes JF, et al
    Education Research: Online Alzheimer education for high school and college students: A randomized controlled trial.
    Neurology. 2020 Jul 14. pii: WNL.0000000000009859.
    PubMed     Abstract available


  90. SUR S, Lin Z, Li Y, Yasar S, et al
    Association of cerebrovascular reactivity and Alzheimer pathologic markers with cognitive performance.
    Neurology. 2020 Jul 13. pii: WNL.0000000000010133.
    PubMed     Abstract available


  91. SWITZER AR, Cheema I, McCreary CR, Zwiers A, et al
    Cerebrovascular reactivity in cerebral amyloid angiopathy, Alzheimer disease, and mild cognitive impairment.
    Neurology. 2020 Jul 8. pii: WNL.0000000000010201.
    PubMed     Abstract available


  92. EBENAU JL, Timmers T, Wesselman LMP, Verberk IMW, et al
    ATN classification and clinical progression in subjective cognitive decline: The SCIENCe project.
    Neurology. 2020;95:e46-e58.
    PubMed     Abstract available


  93. SAKAE N, Santos OA, Pedraza O, Litvan I, et al
    Clinical and pathologic features of cognitive-predominant corticobasal degeneration.
    Neurology. 2020;95:e35-e45.
    PubMed     Abstract available


  94. TEIPEL SJ, Fritz HC, Grothe MJ
    Neuropathological features associated with basal forebrain atrophy in Alzheimer's disease.
    Neurology. 2020 Jul 6. pii: WNL.0000000000010192.
    PubMed     Abstract available


  95. WOLTERS FJ, Chibnik LB, Waziry R, Anderson R, et al
    27-year time trends in dementia incidence in Europe and the US: the Alzheimer Cohorts Consortium.
    Neurology. 2020 Jul 1. pii: WNL.0000000000010022.
    PubMed     Abstract available


    June 2020
  96. TIBLE M, Sandelius A, Hoglund K, Brinkmalm A, et al
    Dissection of synaptic pathways through the CSF biomarkers for predicting Alzheimer's disease.
    Neurology. 2020 Jun 25. pii: WNL.0000000000010131.
    PubMed     Abstract available


  97. RAHMAN A, Schelbaum E, Hoffman K, Diaz I, et al
    Sex-driven modifiers of Alzheimer risk: A multimodality brain imaging study.
    Neurology. 2020 Jun 24. pii: WNL.0000000000009781.
    PubMed     Abstract available


  98. DHANA K, Evans DA, Rajan KB, Bennett DA, et al
    Healthy lifestyle and the risk of Alzheimer dementia: Findings from 2 longitudinal studies.
    Neurology. 2020 Jun 17. pii: WNL.0000000000009816.
    PubMed     Abstract available


  99. BUCIUC M, Botha H, Murray ME, Schwarz CG, et al
    Utility of FDG-PET in diagnosis of Alzheimer-related TDP-43 proteinopathy.
    Neurology. 2020 Jun 9. pii: WNL.0000000000009722.
    PubMed     Abstract available


  100. QIN L, Zhu X, Friedland RP
    ApoE and mitochondrial dysfunction.
    Neurology. 2020;94:1009-1010.
    PubMed    


    May 2020
  101. YIN J, Reiman EM, Beach TG, Serrano GE, et al
    Effect of ApoE isoforms on mitochondria in Alzheimer disease.
    Neurology. 2020 May 26. pii: WNL.0000000000009582.
    PubMed     Abstract available


  102. MATTSSON-CARLGREN N, Leuzy A, Janelidze S, Palmqvist S, et al
    The implications of different approaches to define AT(N) in Alzheimer disease.
    Neurology. 2020 May 12. pii: WNL.0000000000009485.
    PubMed     Abstract available


  103. JACOBS HIL, Augustinack JC, Schultz AP, Hanseeuw BJ, et al
    The presubiculum links incipient amyloid and tau pathology to memory function in older persons.
    Neurology. 2020;94:e1916-e1928.
    PubMed     Abstract available


  104. BERNATH MM, Bhattacharyya S, Nho K, Barupal DK, et al
    Serum triglycerides in Alzheimer disease: Relation to neuroimaging and CSF biomarkers.
    Neurology. 2020 May 1. pii: WNL.0000000000009436.
    PubMed     Abstract available


    April 2020
  105. SMIRNOV DS, Galasko D, Edland SD, Filoteo JV, et al
    Cognitive decline profiles differ in Parkinson disease dementia and dementia with Lewy bodies.
    Neurology. 2020 Apr 24. pii: WNL.0000000000009434.
    PubMed     Abstract available


  106. SARYCHEVA T, Lavikainen P, Taipale H, Tiihonen J, et al
    Antiepileptic drug use and mortality among community-dwelling persons with Alzheimer disease.
    Neurology. 2020 Apr 23. pii: WNL.0000000000009435.
    PubMed     Abstract available


  107. VILAPLANA E, Rodriguez-Vieitez E, Ferreira D, Montal V, et al
    Cortical microstructural correlates of astrocytosis in autosomal dominant Alzheimer disease.
    Neurology. 2020 Apr 14. pii: WNL.0000000000009405.
    PubMed     Abstract available


  108. ARENAZA-URQUIJO EM, Przybelski SA, Machulda MM, Knopman DS, et al
    Better stress coping associated with lower tau in amyloid-positive cognitively unimpaired older adults.
    Neurology. 2020;94:e1571-e1579.
    PubMed     Abstract available


    March 2020
  109. BREITNER J, Meyer PF
    Author response: INTREPAD: A randomized trial of naproxen to slow progress of presymptomatic Alzheimer disease.
    Neurology. 2020;94:594.
    PubMed    


  110. ASHFORD JW
    Reader response: INTREPAD: A randomized trial of naproxen to slow progress of presymptomatic Alzheimer disease.
    Neurology. 2020;94:593-594.
    PubMed    


  111. GANESH A, Galetta S
    Editors' note: INTREPAD: A randomized trial of naproxen to slow progress of presymptomatic Alzheimer disease.
    Neurology. 2020;94:593.
    PubMed    


  112. DOECKE JD, Perez-Grijalba V, Fandos N, Fowler C, et al
    Total Abeta42/Abeta40 ratio in plasma predicts amyloid-PET status, independent of clinical AD diagnosis.
    Neurology. 2020 Mar 16. pii: WNL.0000000000009240.
    PubMed     Abstract available


  113. TERADA T, Obi T, Bunai T, Matsudaira T, et al
    In vivo mitochondrial and glycolytic impairments in patients with Alzheimer disease.
    Neurology. 2020 Mar 5. pii: WNL.0000000000009249.
    PubMed     Abstract available


  114. SWERDLOW RH
    Mitochondria in Alzheimer brains: A PET project shows complex changes.
    Neurology. 2020 Mar 5. pii: WNL.0000000000009236.
    PubMed    


    February 2020
  115. FERREIRA D, Nordberg A, Westman E
    Biological subtypes of Alzheimer disease: A systematic review and meta-analysis.
    Neurology. 2020 Feb 11. pii: WNL.0000000000009058.
    PubMed     Abstract available


  116. HAAKSMA ML, Eriksdotter M, Rizzuto D, Leoutsakos JS, et al
    Survival time tool to guide care planning in people with dementia.
    Neurology. 2020;94:e538-e548.
    PubMed     Abstract available


  117. MCSWEENEY M, Pichet Binette A, Meyer PF, Gonneaud J, et al
    Intermediate flortaucipir uptake is associated with Abeta-PET and CSF-tau in asymptomatic adults.
    Neurology. 2020 Feb 3. pii: WNL.0000000000008905.
    PubMed     Abstract available


    January 2020
  118. RESENDE EPF, Nolan AL, Petersen C, Ehrenberg AJ, et al
    Language and spatial dysfunction in Alzheimer disease with white matter thorn-shaped astrocytes: Astrocytic tau, cognitive function, and Alzheimer disease.
    Neurology. 2020 Jan 30. pii: WNL.0000000000008937.
    PubMed     Abstract available


  119. HOLLAND TM, Agarwal P, Wang Y, Leurgans SE, et al
    Dietary flavonols and risk of Alzheimer dementia.
    Neurology. 2020 Jan 29. pii: WNL.0000000000008981.
    PubMed     Abstract available


  120. MARTERSTECK A, Sridhar J, Rader B, Coventry C, et al
    Differential neurocognitive network perturbation in amnestic and aphasic Alzheimer disease.
    Neurology. 2020 Jan 22. pii: WNL.0000000000008960.
    PubMed     Abstract available


  121. ESPAY AJ, Vizcarra JA, Marsili L, Lang AE, et al
    Author response: Revisiting protein aggregation as pathogenic in sporadic Parkinson and Alzheimer diseases.
    Neurology. 2020;94:144-145.
    PubMed    


  122. NELSON P
    Reader response: Revisiting protein aggregation as pathogenic in sporadic Parkinson and Alzheimer diseases.
    Neurology. 2020;94:143-144.
    PubMed    


  123. SIEGLER JE 3RD, Galetta S
    Editors' note: Revisiting protein aggregation as pathogenic in sporadic Parkinson and Alzheimer diseases.
    Neurology. 2020;94:143.
    PubMed    


  124. WAZIRY R, Chibnik LB, Bos D, Ikram MK, et al
    Risk of hemorrhagic and ischemic stroke in patients with Alzheimer disease: A synthesis of the literature.
    Neurology. 2020 Jan 16. pii: WNL.0000000000008924.
    PubMed     Abstract available


  125. YU L, Boyle PA, Dawe RJ, Bennett DA, et al
    Contribution of TDP and hippocampal sclerosis to hippocampal volume loss in older-old persons.
    Neurology. 2020;94:e142-e152.
    PubMed     Abstract available


    December 2019
  126. SOLDAN A, Pettigrew C, Zhu Y, Wang MC, et al
    White matter hyperintensities and CSF Alzheimer disease biomarkers in preclinical Alzheimer disease.
    Neurology. 2019 Dec 30. pii: WNL.0000000000008864.
    PubMed     Abstract available


  127. CAVEDO E, Lista S, Houot M, Vergallo A, et al
    Plasma tau correlates with basal forebrain atrophy rates in people at risk for Alzheimer disease.
    Neurology. 2019 Dec 4. pii: WNL.0000000000008696.
    PubMed     Abstract available


    November 2019
  128. HONDA T, Ohara T, Shinohara M, Hata J, et al
    Serum elaidic acid concentration and risk of dementia: The Hisayama Study.
    Neurology. 2019;93:e2053-e2064.
    PubMed     Abstract available


  129. GRAFF-RADFORD J, Gunter JL, Jones DT, Przybelski SA, et al
    Cerebrospinal fluid dynamics disorders: Relationship to Alzheimer biomarkers and cognition.
    Neurology. 2019 Nov 12. pii: WNL.0000000000008616.
    PubMed     Abstract available


  130. WEINTRAUB S, Teylan M, Rader B, Chan KCG, et al
    APOE is a correlate of phenotypic heterogeneity in Alzheimer disease in a national cohort.
    Neurology. 2019 Nov 8. pii: WNL.0000000000008666.
    PubMed     Abstract available


    October 2019
  131. NETH BJ
    Right brain: Art and the restoration of identity in dementia.
    Neurology. 2019;93:719-721.
    PubMed    


  132. CHONG JSX, Jang H, Kim HJ, Ng KK, et al
    Amyloid and cerebrovascular burden divergently influence brain functional network changes over time.
    Neurology. 2019;93:e1514-e1525.
    PubMed     Abstract available


  133. SCHNEIDER LS, Geffen Y, Rabinowitz J, Thomas RG, et al
    Low-dose ladostigil for mild cognitive impairment: A phase 2 placebo-controlled clinical trial.
    Neurology. 2019;93:e1474-e1484.
    PubMed     Abstract available


  134. MIRZA SS, Saeed U, Knight J, Ramirez J, et al
    APOE varepsilon4, white matter hyperintensities, and cognition in Alzheimer and Lewy body dementia.
    Neurology. 2019 Oct 1. pii: WNL.0000000000008377.
    PubMed     Abstract available


    August 2019

  135. INTREPAD: A randomized trial of naproxen to slow progress of presymptomatic Alzheimer disease.
    Neurology. 2019;93:371.
    PubMed    


  136. BENDLIN BB, Zetterberg H
    Screening with a high precision blood-based assay for Alzheimer disease.
    Neurology. 2019 Aug 1. pii: WNL.0000000000008080.
    PubMed    


    July 2019
  137. WOLTERS FJ, Zonneveld HI, Licher S, Cremers LGM, et al
    Hemoglobin and anemia in relation to dementia risk and accompanying changes on brain MRI.
    Neurology. 2019 Jul 31. pii: WNL.0000000000008003.
    PubMed     Abstract available


  138. QIU Y, Jacobs DM, Messer K, Salmon DP, et al
    Cognitive heterogeneity in probable Alzheimer disease: Clinical and neuropathologic features.
    Neurology. 2019 Jul 18. pii: WNL.0000000000007967.
    PubMed     Abstract available



  139. Clinical phenotype, atrophy, and small vessel disease in APOEepsilon2 carriers with Alzheimer disease.
    Neurology. 2019;93:135.
    PubMed    


  140. INSEL PS, Weiner M, Mackin RS, Mormino E, et al
    Determining clinically meaningful decline in preclinical Alzheimer disease.
    Neurology. 2019 Jul 9. pii: WNL.0000000000007831.
    PubMed     Abstract available


  141. HAN SD, Shinotoh H
    The search for meaning in preclinical Alzheimer disease clinical trials.
    Neurology. 2019 Jul 9. pii: WNL.0000000000007817.
    PubMed    


  142. BISCHOF GN, Jacobs HIL
    Subthreshold amyloid and its biological and clinical meaning: Long way ahead.
    Neurology. 2019;93:72-79.
    PubMed     Abstract available


  143. VAN LOENHOUD AC, van der Flier WM, Wink AM, Dicks E, et al
    Cognitive reserve and clinical progression in Alzheimer disease: A paradoxical relationship.
    Neurology. 2019 Jul 2. pii: WNL.0000000000007821.
    PubMed     Abstract available


    June 2019
  144. TAGHDIRI F, Multani N, Tarazi A, Naeimi SA, et al
    Elevated cerebrospinal fluid total tau in former professional athletes with multiple concussions.
    Neurology. 2019;92:e2717-e2726.
    PubMed     Abstract available


    May 2019
  145. VERMUNT L, van Paasen AJL, Teunissen CE, Scheltens P, et al
    Alzheimer disease biomarkers may aid in the prognosis of MCI cases initially reverted to normal.
    Neurology. 2019 May 8. pii: WNL.0000000000007609.
    PubMed     Abstract available


    April 2019
  146. KARCESKI S, Karceski S
    Can naproxen slow the progression of Alzheimer disease?
    Neurology. 2019;92:e2181-e2184.
    PubMed    


  147. KNOPMAN DS, Petersen RC, Jack CR Jr
    A brief history of "Alzheimer disease": Multiple meanings separated by a common name.
    Neurology. 2019 Apr 26. pii: WNL.0000000000007583.
    PubMed     Abstract available


  148. ERICKSON CM, Schultz SA, Oh JM, Darst BF, et al
    KLOTHO heterozygosity attenuates APOE4-related amyloid burden in preclinical AD.
    Neurology. 2019;92:e1878-e1889.
    PubMed     Abstract available


  149. ARVANITAKIS Z, Capuano AW
    Author response: Late-life blood pressure association with cerebrovascular and Alzheimer disease pathology.
    Neurology. 2019;92:732.
    PubMed    


  150. LATTANZI S, Silvestrini M
    Reader response: Late-life blood pressure association with cerebrovascular and Alzheimer disease pathology.
    Neurology. 2019;92:731.
    PubMed    


  151. SIEGLER JE 3RD, Galetta S
    Editors' note: Late-life blood pressure association with cerebrovascular and Alzheimer disease pathology.
    Neurology. 2019;92:731.
    PubMed    


  152. MEYER PF, Tremblay-Mercier J, Leoutsakos J, Madjar C, et al
    INTREPAD: A randomized trial of naproxen to slow progress of presymptomatic Alzheimer disease.
    Neurology. 2019 Apr 5. pii: WNL.0000000000007232.
    PubMed     Abstract available


  153. HERSHEY LA, Lipton RB
    Naproxen for presymptomatic Alzheimer disease: Is this the end, or shall we try again?
    Neurology. 2019 Apr 5. pii: WNL.0000000000007233.
    PubMed    


  154. KANG SW, Jeon S, Yoo HS, Chung SJ, et al
    Effects of Lewy body disease and Alzheimer disease on brain atrophy and cognitive dysfunction.
    Neurology. 2019 Apr 3. pii: WNL.0000000000007373.
    PubMed     Abstract available


  155. SOLDAN A, Pettigrew C, Fagan AM, Schindler SE, et al
    ATN profiles among cognitively normal individuals and longitudinal cognitive outcomes.
    Neurology. 2019;92:e1567-e1579.
    PubMed     Abstract available


    March 2019
  156. SATHYAN S, Wang T, Ayers E, Verghese J, et al
    Genetic basis of motoric cognitive risk syndrome in the Health and Retirement Study.
    Neurology. 2019;92:e1427-e1434.
    PubMed     Abstract available


  157. CANNON-ALBRIGHT LA, Foster NL, Schliep K, Farnham JM, et al
    Relative risk for Alzheimer disease based on complete family history.
    Neurology. 2019 Mar 13. pii: WNL.0000000000007231.
    PubMed     Abstract available


  158. VAN HARTEN AC
    Longevity gene KLOTHO may play a role in Alzheimer disease.
    Neurology. 2019 Mar 13. pii: WNL.0000000000007302.
    PubMed    


  159. VOS SJB, Duara R
    The prognostic value of ATN Alzheimer biomarker profiles in cognitively normal individuals.
    Neurology. 2019 Mar 6. pii: WNL.0000000000007223.
    PubMed    


  160. MESULAM MM, Lalehzari N, Rahmani F, Ohm D, et al
    Cortical cholinergic denervation in primary progressive aphasia with Alzheimer pathology.
    Neurology. 2019 Mar 6. pii: WNL.0000000000007247.
    PubMed     Abstract available


  161. PRESSMAN PS, Gola K, Shdo SM, Miller BL, et al
    Relative preservation of facial expression recognition in posterior cortical atrophy.
    Neurology. 2019;92:e1064-e1071.
    PubMed     Abstract available


    February 2019
  162. FEMMINELLA GD, Dani M, Wood M, Fan Z, et al
    Microglial activation in early Alzheimer trajectory is associated with higher gray matter volume.
    Neurology. 2019 Feb 22. pii: WNL.0000000000007133.
    PubMed     Abstract available


  163. WILSON RS, Yang J, Yu L, Leurgans SE, et al
    Postmortem neurodegenerative markers and trajectories of decline in cognitive systems.
    Neurology. 2019;92:e831-e840.
    PubMed     Abstract available


  164. MORAN C, Beare R, Wang W, Callisaya M, et al
    Type 2 diabetes mellitus, brain atrophy, and cognitive decline.
    Neurology. 2019;92:e823-e830.
    PubMed     Abstract available


  165. BUCHMAN AS, Yu L, Wilson RS, Lim A, et al
    Physical activity, common brain pathologies, and cognition in community-dwelling older adults.
    Neurology. 2019;92:e811-e822.
    PubMed     Abstract available


  166. ESPAY AJ, Vizcarra JA, Marsili L, Lang AE, et al
    Revisiting protein aggregation as pathogenic in sporadic Parkinson and Alzheimer diseases.
    Neurology. 2019;92:329-337.
    PubMed     Abstract available


    January 2019
  167. WHITWELL JL, Martin PR, Duffy JR, Clark HM, et al
    The influence of beta-amyloid on [(18)F]AV-1451 in semantic variant of primary progressive aphasia.
    Neurology. 2019 Jan 11. pii: WNL.0000000000006913.
    PubMed     Abstract available


  168. OSSENKOPPELE R, Smith R, Ohlsson T, Strandberg O, et al
    Associations between tau, Abeta, and cortical thickness with cognition in Alzheimer disease.
    Neurology. 2019 Jan 9. pii: WNL.0000000000006875.
    PubMed     Abstract available


  169. KANTARCI K, Jicha GA
    Development of (1)H MRS biomarkers for tracking early predementia Alzheimer disease.
    Neurology. 2019 Jan 4. pii: WNL.0000000000006839.
    PubMed    


    December 2018
  170. HARA Y, McKeehan N, Fillit HM
    Translating the biology of aging into novel therapeutics for Alzheimer disease.
    Neurology. 2018 Dec 7. pii: WNL.0000000000006745.
    PubMed     Abstract available


    October 2018
  171. GROOT C, Sudre CH, Barkhof F, Teunissen CE, et al
    Clinical phenotype, atrophy, and small vessel disease in APOEepsilon2 carriers with Alzheimer disease.
    Neurology. 2018 Oct 19. pii: WNL.0000000000006503.
    PubMed     Abstract available


  172. KORK F, Jankowski J, Goswami A, Weis J, et al
    Golgin A4 in CSF and granulovacuolar degenerations of Alzheimer patients.
    Neurology. 2018 Oct 10. pii: WNL.0000000000006457.
    PubMed     Abstract available


    September 2018
  173. BRICKMAN AM, Tosto G, Gutierrez J, Andrews H, et al
    An MRI measure of degenerative and cerebrovascular pathology in Alzheimer disease.
    Neurology. 2018 Sep 14. pii: WNL.0000000000006310.
    PubMed     Abstract available


  174. MCDADE E, Wang G, Gordon BA, Hassenstab J, et al
    Longitudinal cognitive and biomarker changes in dominantly inherited Alzheimer disease.
    Neurology. 2018 Sep 14. pii: WNL.0000000000006277.
    PubMed     Abstract available


  175. BENNETT DA
    An MRI biomarker of mixed pathology.
    Neurology. 2018 Sep 14. pii: WNL.0000000000006305.
    PubMed    


    August 2018
  176. DICKSON DW, Heckman MG, Murray ME, Soto AI, et al
    APOE epsilon4 is associated with severity of Lewy body pathology independent of Alzheimer pathology.
    Neurology. 2018 Aug 24. pii: WNL.0000000000006212.
    PubMed     Abstract available


  177. PETERSEN RC
    How early can we diagnose Alzheimer disease (and is it sufficient)? The 2017 Wartenberg lecture.
    Neurology. 2018 Aug 8. pii: WNL.0000000000006088.
    PubMed     Abstract available


  178. ASCHENBRENNER AJ, Gordon BA, Benzinger TLS, Morris JC, et al
    Influence of tau PET, amyloid PET, and hippocampal volume on cognition in Alzheimer disease.
    Neurology. 2018 Aug 1. pii: WNL.0000000000006075.
    PubMed     Abstract available


    July 2018

  179. Age-dependent white matter inflammation and cognitive impairment in the TgAPP21 rat model of Alzheimer disease.
    Neurology. 2018;91:242.
    PubMed    


  180. JANELIDZE S, Mattsson N, Stomrud E, Lindberg O, et al
    CSF biomarkers of neuroinflammation and cerebrovascular dysfunction in early Alzheimer disease.
    Neurology. 2018 Jul 27. pii: WNL.0000000000006082.
    PubMed     Abstract available


  181. JANG H, Bae JB, Dardiotis E, Scarmeas N, et al
    Differential effects of completed and incomplete pregnancies on the risk of Alzheimer disease.
    Neurology. 2018 Jul 18. pii: WNL.0000000000006000.
    PubMed     Abstract available


  182. ARVANITAKIS Z, Capuano AW, Lamar M, Shah RC, et al
    Late-life blood pressure association with cerebrovascular and Alzheimer disease pathology.
    Neurology. 2018 Jul 11. pii: WNL.0000000000005951.
    PubMed     Abstract available


    June 2018
  183. STRAIN JF, Smith RX, Beaumont H, Roe CM, et al
    Loss of white matter integrity reflects tau accumulation in Alzheimer disease defined regions.
    Neurology. 2018 Jun 29. pii: WNL.0000000000005864.
    PubMed     Abstract available


  184. MERLUZZI AP, Carlsson CM, Johnson SC, Schindler SE, et al
    Neurodegeneration, synaptic dysfunction, and gliosis are phenotypic of Alzheimer dementia.
    Neurology. 2018 Jun 29. pii: WNL.0000000000005901.
    PubMed     Abstract available


  185. BENARROCH EE
    Glutamatergic synaptic plasticity and dysfunction in Alzheimer disease: Emerging mechanisms.
    Neurology. 2018 Jun 13. pii: WNL.0000000000005807.
    PubMed    


    April 2018
  186. PASSAMONTI L, Rodriguez PV, Hong YT, Allinson KSJ, et al
    [(11)C]PK11195 binding in Alzheimer disease and progressive supranuclear palsy.
    Neurology. 2018 Apr 27. pii: WNL.0000000000005610.
    PubMed     Abstract available


  187. CUMMINGS JL, Cohen S, van Dyck CH, Brody M, et al
    ABBY: A phase 2 randomized trial of crenezumab in mild to moderate Alzheimer disease.
    Neurology. 2018 Apr 25. pii: WNL.0000000000005550.
    PubMed     Abstract available


  188. BERTI V, Walters M, Sterling J, Quinn CG, et al
    Mediterranean diet and 3-year Alzheimer brain biomarker changes in middle-aged adults.
    Neurology. 2018 Apr 13. pii: WNL.0000000000005527.
    PubMed     Abstract available


  189. KERN S, Zetterberg H, Kern J, Zettergren A, et al
    Prevalence of preclinical Alzheimer disease: Comparison of current classification systems.
    Neurology. 2018 Apr 13. pii: WNL.0000000000005476.
    PubMed     Abstract available


    March 2018
  190. ARENAZA-URQUIJO EM, Vemuri P
    Resistance vs resilience to Alzheimer disease: Clarifying terminology for preclinical studies.
    Neurology. 2018 Mar 28. pii: WNL.0000000000005303.
    PubMed     Abstract available


    February 2018
  191. BENNETT DA, Gordon BA
    Alzheimer disease biomarkers and synucleinopathy.
    Neurology. 2018 Feb 21. pii: WNL.0000000000005171.
    PubMed    


  192. MENDES A, Bertrand A, Lamari F, Colliot O, et al
    Cerebral microbleeds and CSF Alzheimer biomarkers in primary progressive aphasias.
    Neurology. 2018 Feb 14. pii: WNL.0000000000005165.
    PubMed     Abstract available


  193. JONES DT, Knopman DS, Graff-Radford J, Syrjanen JA, et al
    In vivo (18)F-AV-1451 tau-PET signal in MAPT mutation carriers varies by expected tau isoforms.
    Neurology. 2018 Feb 9. pii: WNL.0000000000005117.
    PubMed     Abstract available


  194. BOTHA H, Mantyh WG, Graff-Radford J, Machulda MM, et al
    Tau-negative amnestic dementia masquerading as Alzheimer disease dementia.
    Neurology. 2018 Feb 7. pii: WNL.0000000000005124.
    PubMed     Abstract available


  195. DAY GS, Gordon BA, Perrin RJ, Cairns NJ, et al
    In vivo [(18)F]-AV-1451 tau-PET imaging in sporadic Creutzfeldt-Jakob disease.
    Neurology. 2018 Feb 7. pii: WNL.0000000000005064.
    PubMed     Abstract available


  196. KNOPMAN DS
    Sifting through a failed Alzheimer trial: What biomarkers tell us about what happened.
    Neurology. 2018 Feb 2. pii: WNL.0000000000005073.
    PubMed    


    January 2018
  197. AISEN PS
    Author response: A phase 3 trial of IV immunoglobulin for Alzheimer disease.
    Neurology. 2018;90:145.
    PubMed    


  198. PIAZZA F
    Reader response: A phase 3 trial of IV immunoglobulin for Alzheimer disease.
    Neurology. 2018;90:144-145.
    PubMed    


  199. KARAM C, Griggs RC
    Editors' note: A phase 3 trial of IV immunoglobulin for Alzheimer disease.
    Neurology. 2018;90:144.
    PubMed    


  200. MATTSSON N, Smith R, Strandberg O, Palmqvist S, et al
    Comparing (18)F-AV-1451 with CSF t-tau and p-tau for diagnosis of Alzheimer disease.
    Neurology. 2018 Jan 10. pii: WNL.0000000000004887.
    PubMed     Abstract available


    December 2017
  201. WILLIAMS DM, Karlsson IK, Pedersen NL, Hagg S, et al
    Circulating insulin-like growth factors and Alzheimer disease: A mendelian randomization study.
    Neurology. 2017 Dec 27. pii: WNL.0000000000004854.
    PubMed     Abstract available


  202. YASAR S, Whitmer R
    Statin use and risk of Alzheimer disease: A new view on an old relationship.
    Neurology. 2017 Dec 15. pii: WNL.0000000000004837.
    PubMed    


  203. SINYAVSKAYA L, Gauthier S, Renoux C, Dell'Aniello S, et al
    Comparative effect of statins on the risk of incident Alzheimer disease.
    Neurology. 2017 Dec 15. pii: WNL.0000000000004818.
    PubMed     Abstract available


  204. GROOT C, van Loenhoud AC, Barkhof F, van Berckel BNM, et al
    Differential effects of cognitive reserve and brain reserve on cognition in Alzheimer disease.
    Neurology. 2017 Dec 13. pii: WNL.0000000000004802.
    PubMed     Abstract available


  205. GONNEAUD J, Arenaza-Urquijo EM, Mezenge F, Landeau B, et al
    Increased florbetapir binding in the temporal neocortex from age 20 to 60 years.
    Neurology. 2017;89:2438-2446.
    PubMed     Abstract available


    November 2017
  206. GROTHE MJ, Barthel H, Sepulcre J, Dyrba M, et al
    In vivo staging of regional amyloid deposition.
    Neurology. 2017;89:2031-2038.
    PubMed     Abstract available


  207. CORRIVEAU RA, Koroshetz WJ, Gladman JT, Jeon S, et al
    Alzheimer's Disease-Related Dementias Summit 2016: National research priorities.
    Neurology. 2017 Nov 8. pii: 10.1212/WNL.0000000000004717.
    PubMed     Abstract available


    October 2017
  208. GAUTHIER S, Ng KP, Pascoal TA, Mathotaarachchi S, et al
    Author response: Neuropsychiatric symptoms predict hypometabolism in preclinical Alzheimer disease.
    Neurology. 2017;89:1931.
    PubMed    


  209. LANDIN-ROMERO R, Kumfor F
    Letter re: Neuropsychiatric symptoms predict hypometabolism in preclinical Alzheimer disease.
    Neurology. 2017;89:1931.
    PubMed    


  210. RISACHER SL, Anderson WH, Charil A, Castelluccio PF, et al
    Alzheimer disease brain atrophy subtypes are associated with cognition and rate of decline.
    Neurology. 2017 Oct 25. pii: 10.1212/WNL.0000000000004670.
    PubMed     Abstract available


  211. WESTON PSJ, Poole T, Ryan NS, Nair A, et al
    Serum neurofilament light in familial Alzheimer disease: A marker of early neurodegeneration.
    Neurology. 2017 Oct 25. pii: 10.1212/WNL.0000000000004667.
    PubMed     Abstract available


  212. FILIPPI M, Basaia S, Canu E, Imperiale F, et al
    Brain network connectivity differs in early-onset neurodegenerative dementia.
    Neurology. 2017;89:1764-1772.
    PubMed     Abstract available


  213. BRENOWITZ WD, Hubbard RA, Keene CD, Hawes SE, et al
    Mixed neuropathologies and associations with domain-specific cognitive decline.
    Neurology. 2017;89:1773-1781.
    PubMed     Abstract available


  214. CHETELAT G, Murray ME
    Amyloid PET scan: Staging beyond reading?
    Neurology. 2017 Oct 18. pii: 10.1212/WNL.0000000000004678.
    PubMed    


  215. KIEBOOM BCT, Licher S, Wolters FJ, Ikram MK, et al
    Serum magnesium is associated with the risk of dementia.
    Neurology. 2017;89:1716-1722.
    PubMed     Abstract available


  216. ROBERTS RO, Knopman DS, Syrjanen JA, Aakre JA, et al
    Weighting and standardization of frequencies to determine prevalence of AD imaging biomarkers.
    Neurology. 2017 Oct 13. pii: 10.1212/WNL.0000000000004652.
    PubMed     Abstract available


  217. GASBY D
    Alzheimer dementia's other victim: The spouse.
    Neurology. 2017 Oct 6. pii: 10.1212/WNL.0000000000004638.
    PubMed    


  218. WEINER MW, Crane PK, Montine TJ, Bennett DA, et al
    Traumatic brain injury may not increase the risk of Alzheimer disease.
    Neurology. 2017 Oct 4. pii: 10.1212/WNL.0000000000004608.
    PubMed     Abstract available


    September 2017
  219. MEDAGLIA JD, Huang W, Segarra S, Olm C, et al
    Brain network efficiency is influenced by the pathologic source of corticobasal syndrome.
    Neurology. 2017;89:1373-1381.
    PubMed     Abstract available


  220. CASALETTO KB, Elahi FM, Bettcher BM, Neuhaus J, et al
    Neurogranin, a synaptic protein, is associated with memory independent of Alzheimer biomarkers.
    Neurology. 2017 Sep 22. pii: 10.1212/WNL.0000000000004569.
    PubMed     Abstract available


  221. NORTON DJ, Amariglio R, Protas H, Chen K, et al
    Subjective memory complaints in preclinical autosomal dominant Alzheimer disease.
    Neurology. 2017 Sep 6. pii: 10.1212/WNL.0000000000004533.
    PubMed     Abstract available


    August 2017
  222. MOSCONI L, Berti V, Quinn C, McHugh P, et al
    Sex differences in Alzheimer risk: Brain imaging of endocrine vs chronologic aging.
    Neurology. 2017 Aug 30. pii: 10.1212/WNL.0000000000004425.
    PubMed     Abstract available



  223. Short-term clinical outcomes for stages of NIA-AA preclinical Alzheimer disease.
    Neurology. 2017;89:980.
    PubMed    


  224. SMITH R, Scholl M, Widner H, van Westen D, et al
    In vivo retention of 18F-AV-1451 in corticobasal syndrome.
    Neurology. 2017;89:845-853.
    PubMed     Abstract available


  225. LI G, Mayer CL, Morelli D, Millard SP, et al
    Effect of simvastatin on CSF Alzheimer disease biomarkers in cognitively normal adults.
    Neurology. 2017 Aug 18. pii: 10.1212/WNL.0000000000004392.
    PubMed     Abstract available


    July 2017
  226. BENUSSI A, Di Lorenzo F, Dell'Era V, Cosseddu M, et al
    Transcranial magnetic stimulation distinguishes Alzheimer disease from frontotemporal dementia.
    Neurology. 2017 Jul 26. pii: 10.1212/WNL.0000000000004232.
    PubMed     Abstract available


  227. DONADIO V, Incensi A, Rizzo G, Capellari S, et al
    A new potential biomarker for dementia with Lewy bodies: Skin nerve alpha-synuclein deposits.
    Neurology. 2017;89:318-326.
    PubMed     Abstract available


  228. LAFAILLE-MAGNAN ME, Poirier J, Etienne P, Tremblay-Mercier J, et al
    Odor identification as a biomarker of preclinical AD in older adults at risk.
    Neurology. 2017;89:327-335.
    PubMed     Abstract available


  229. SPIRA AP, Ju YS
    Self-reported sleep and Alzheimer disease CSF biomarkers: A wake-up call.
    Neurology. 2017 Jul 5. pii: 10.1212/WNL.0000000000004189.
    PubMed    


  230. MOFFAT SD
    Author response: Long-term cortisol measures predict Alzheimer disease risk.
    Neurology. 2017;89:106.
    PubMed    


  231. LATTANZI S, Silvestrini M
    Letter re: Long-term cortisol measures predict Alzheimer disease risk.
    Neurology. 2017;89:106.
    PubMed    


    June 2017
  232. ZHAN X
    Author response: Gram-negative bacterial molecules associate with Alzheimer disease pathology.
    Neurology. 2017;88:2338.
    PubMed    


  233. MENTE K
    Letter re: Gram-negative bacterial molecules associate with Alzheimer disease pathology.
    Neurology. 2017;88:2338.
    PubMed    


  234. BUCKLEY RF, Schultz AP, Hedden T, Papp KV, et al
    Functional network integrity presages cognitive decline in preclinical Alzheimer disease.
    Neurology. 2017 Jun 7. pii: 10.1212/WNL.0000000000004059.
    PubMed     Abstract available


  235. ALCOLEA D, Vilaplana E, Suarez-Calvet M, Illan-Gala I, et al
    CSF sAPPbeta, YKL-40, and neurofilament light in frontotemporal lobar degeneration.
    Neurology. 2017 Jun 7. pii: 10.1212/WNL.0000000000004088.
    PubMed     Abstract available


    May 2017
  236. GIANNINI LAA, Irwin DJ, McMillan CT, Ash S, et al
    Clinical marker for Alzheimer disease pathology in logopenic primary progressive aphasia.
    Neurology. 2017 May 17. pii: 10.1212/WNL.0000000000004034.
    PubMed     Abstract available


  237. BOOTS EA, Schultz SA, Clark LR, Racine AM, et al
    BDNF Val66Met predicts cognitive decline in the Wisconsin Registry for Alzheimer's Prevention.
    Neurology. 2017 May 3. pii: 10.1212/WNL.0000000000003980.
    PubMed     Abstract available


    April 2017
  238. SCHULTZ SA, Boots EA, Darst BF, Zetterberg H, et al
    Cardiorespiratory fitness alters the influence of a polygenic risk score on biomarkers of AD.
    Neurology. 2017;88:1650-1658.
    PubMed     Abstract available


  239. NG KP, Pascoal TA, Mathotaarachchi S, Chung CO, et al
    Neuropsychiatric symptoms predict hypometabolism in preclinical Alzheimer disease.
    Neurology. 2017 Apr 12. pii: 10.1212/WNL.0000000000003916.
    PubMed     Abstract available


  240. PETERSEN RC, Thomas RG, Aisen PS, Mohs RC, et al
    Randomized controlled trials in mild cognitive impairment: Sources of variability.
    Neurology. 2017 Apr 5. pii: 10.1212/WNL.0000000000003907.
    PubMed     Abstract available


  241. RELKIN NR, Thomas RG, Rissman RA, Brewer JB, et al
    A phase 3 trial of IV immunoglobulin for Alzheimer disease.
    Neurology. 2017 Apr 5. pii: 10.1212/WNL.0000000000003904.
    PubMed     Abstract available


    March 2017
  242. PAPP KV, Rentz DM, Mormino EC, Schultz AP, et al
    Cued memory decline in biomarker-defined preclinical Alzheimer disease.
    Neurology. 2017 Mar 10. pii: 10.1212/WNL.0000000000003812.
    PubMed     Abstract available


    February 2017
  243. DAY GS, Lim TS, Hassenstab J, Goate AM, et al
    Differentiating cognitive impairment due to corticobasal degeneration and Alzheimer disease.
    Neurology. 2017 Feb 24. pii: 10.1212/WNL.0000000000003770.
    PubMed     Abstract available


  244. TOSTO G, Bird TD, Tsuang D, Bennett DA, et al
    Polygenic risk scores in familial Alzheimer disease.
    Neurology. 2017 Feb 17. pii: 10.1212/WNL.0000000000003734.
    PubMed     Abstract available


  245. IMTIAZ B, Tuppurainen M, Rikkonen T, Kivipelto M, et al
    Postmenopausal hormone therapy and Alzheimer disease: A prospective cohort study.
    Neurology. 2017 Feb 15. pii: 10.1212/WNL.0000000000003696.
    PubMed     Abstract available


  246. CHEN J, Yu JT, Wojta K, Wang HF, et al
    Genome-wide association study identifies MAPT locus influencing human plasma tau levels.
    Neurology. 2017;88:669-676.
    PubMed     Abstract available


  247. FRANZMEIER N, Duering M, Weiner M, Dichgans M, et al
    Left frontal cortex connectivity underlies cognitive reserve in prodromal Alzheimer disease.
    Neurology. 2017 Feb 10. pii: 10.1212/WNL.0000000000003711.
    PubMed     Abstract available


  248. KREISL WC, Lawrence R, Page E, Teich AF, et al
    11C-PBR28 PET detects translocator protein in a patient with astrocytoma and Alzheimer disease.
    Neurology. 2017 Feb 8. pii: 10.1212/WNL.0000000000003693.
    PubMed    


    January 2017
  249. FEDOROVA TD, Seidelin LB, Knudsen K, Schacht AC, et al
    Decreased intestinal acetylcholinesterase in early Parkinson disease: An 11C-donepezil PET study.
    Neurology. 2017 Jan 18. pii: 10.1212/WNL.0000000000003633.
    PubMed     Abstract available


  250. THOMAS AJ, Attems J, Colloby SJ, O'Brien JT, et al
    Autopsy validation of 123I-FP-CIT dopaminergic neuroimaging for the diagnosis of DLB.
    Neurology. 2017;88:276-283.
    PubMed     Abstract available


    December 2016
  251. ENNIS GE, An Y, Resnick SM, Ferrucci L, et al
    Long-term cortisol measures predict Alzheimer disease risk.
    Neurology. 2016 Dec 16. pii: 10.1212/WNL.0000000000003537.
    PubMed     Abstract available


    November 2016
  252. MOKRY LE, Ross S, Morris JA, Manousaki D, et al
    Genetically decreased vitamin D and risk of Alzheimer disease.
    Neurology. 2016 Nov 16. pii: 10.1212/WNL.0000000000003430.
    PubMed     Abstract available


  253. HOHMAN TJ, McLaren DG, Mormino EC, Gifford KA, et al
    Asymptomatic Alzheimer disease: Defining resilience.
    Neurology. 2016 Nov 4. pii: 10.1212/WNL.0000000000003397.
    PubMed     Abstract available


    October 2016
  254. KIKUCHI A, Okamura N, Hasegawa T, Harada R, et al
    In vivo visualization of tau deposits in corticobasal syndrome by 18F-THK5351 PET.
    Neurology. 2016 Oct 28. pii: 10.1212/WNL.0000000000003375.
    PubMed     Abstract available


  255. ZHAN X, Stamova B, Jin LW, DeCarli C, et al
    Gram-negative bacterial molecules associate with Alzheimer disease pathology.
    Neurology. 2016 Oct 26. pii: 10.1212/WNL.0000000000003391.
    PubMed     Abstract available


  256. WESTON PS, Nicholas JM, Lehmann M, Ryan NS, et al
    Presymptomatic cortical thinning in familial Alzheimer disease: A longitudinal MRI study.
    Neurology. 2016 Oct 12. pii: 10.1212/WNL.0000000000003322.
    PubMed     Abstract available


  257. MATTIS PJ, Niethammer M, Sako W, Tang CC, et al
    Distinct brain networks underlie cognitive dysfunction in Parkinson and Alzheimer diseases.
    Neurology. 2016 Oct 5. pii: 10.1212/WNL.0000000000003285.
    PubMed     Abstract available


    September 2016
  258. MATTSSON N, Zetterberg H, Janelidze S, Insel PS, et al
    Plasma tau in Alzheimer disease.
    Neurology. 2016 Sep 30. pii: 10.1212/WNL.0000000000003246.
    PubMed     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Alzheimer's Disease is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: